Quick Facts at a Glance
- Recall Date
- December 18, 2025
- Hazard Level
- HIGH
- Brand
- Imprimis NJOF
- Category
- Health & Personal Care
- Sold At
- Unknown
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- Imprimis NJOF
- Product type
- Intraocular Injection
- Model numbers
- Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
- Sold at
- Unknown
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
December 18, 2025
Reported by FDA DRUG
January 14, 2026
RecallRadar source check
January 21, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Presence of particulate matter - Glass like particles.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Imprimis NJOF, LLC or your healthcare provider for guidance. Notification method: Letter
About This Product
Tri-Moxi+¿ is a single-use intraocular injection combining triamcinolone and moxifloxacin, commonly used to treat eye conditions. Patients typically receive this injection during eye surgeries or to manage inflammation and prevent infections.
Why This Is Dangerous
The presence of glass-like particles in the injection poses a risk of injury to the eye, which could lead to serious complications. These particles can interfere with normal vision and cause pain or infection.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
The recall affects patients who may have received or are scheduled to receive this injection. It poses a serious health risk due to potential complications from the glass particles.
Practical Guidance
How to identify if yours is affected
- Check the lot number on your injection.
- Verify if it matches 25JAN033A or 25JAN033B.
- Examine the expiration date to ensure it is before February 12, 2026.
Where to find product info
Lot numbers and expiration dates can typically be found on the packaging of the injection syringes.
What timeline to expect
Expect a response regarding refunds or replacements within 4-6 weeks after contacting the manufacturer.
If the manufacturer is unresponsive
- Contact Imprimis NJOF directly for assistance.
- Document all communications and attempts to resolve the issue.
How to prevent similar issues
- Always check for recalls before using medical products.
- Request information on product safety from your healthcare provider.
Documentation advice
Keep records of your purchase, including receipts and correspondence with the manufacturer or healthcare provider.
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
The recalled product is Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6mg/0.6mL) Single-Use Intraocular Injection. Lot numbers include 25JAN033A and 25JAN033B, with an expiration date of February 12, 2026. The product was distributed nationally across the United States.
Key Facts
- Recall date: December 18, 2025
- Class II recall due to glass particles
- 314 boxes of 6,280 pre-filled syringes recalled
- Contact healthcare provider for guidance
- Distribution: U.S. Nationwide
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.
